RAP1A

Ras-related protein Rap-1A · P62834 · RAP1A on Sugi Atlas →

76 patent compounds predicted against RAP1A, 74 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Yessotoxin (SCHEMBL29683417)	1.00	2/20
SCHEMBL28998123	0.75	2/20
SCHEMBL28998119	0.72	2/20
SCHEMBL29934491	0.60	2/20
SCHEMBL30502878	0.55	2/20
SCHEMBL15503083	0.53	2/20
SCHEMBL13947381	0.36	2/20
SCHEMBL14043530	0.35	2/20
SCHEMBL29374346	0.35	2/20
SCHEMBL13947373	0.34	2/20
SCHEMBL13947382	0.34	2/20
SCHEMBL13947371	0.34	2/20
Brevetoxin (SCHEMBL29375020)	0.34	2/20
SCHEMBL12908960	0.33	2/20
SCHEMBL13947377	0.33	2/20
SCHEMBL10130545	0.33	2/20
Brevetoxin B (SCHEMBL869360)	0.33	2/20
SCHEMBL10130542	0.33	2/20
Alpha-Bungarotoxin (SCHEMBL14043478)	0.33	2/20
Alpha-Bungarotoxin (SCHEMBL14106557)	0.33	2/20

Clinical trials — most relevant to RAP1A by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
NEO100 and High-Grade Meningioma	PHASE2	RECRUITING
Antioxidant Therapy With N-acetylcysteine for Learning and Motor Behavior in Children With Neurofibromatosis Type 1	PHASE2	COMPLETED
R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas	PHASE2	COMPLETED
BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC	PHASE2	COMPLETED
Antioxidant Therapy With N-acetylcysteine for Children With Neurofibromatosis Type 1	PHASE2	COMPLETED
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma	PHASE1/PHASE2	SUSPENDED
BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer	PHASE2	COMPLETED
Use of RAD001 as Monotherapy in the Treatment of Neurofibromatosis 1 Related Internal Plexiform Neurofibromas	PHASE2	COMPLETED
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma	PHASE1/PHASE2	RECRUITING
A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma	PHASE1/PHASE2	COMPLETED
Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer	PHASE2	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
FAK Inhibitor in Patients With Advanced Solid Tumors	PHASE1	NOT_YET_RECRUITING
Expression and Function of the Renin-Angiotensin System in the Esophagus	EARLY_PHASE1	COMPLETED
Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies	nan	RECRUITING
Acceptance and Commitment Therapy for Caregivers of Children With a RASopathy: An Internal Pilot Feasibility Study and Follow-up Randomized Controlled Trial	nan	RECRUITING
Prospective Validation of a DNA Damage Repair-Hippo Pathway Signature in Patients With Advanced Gastric Cancer	nan	UNKNOWN
Clinical Genetics Branch Eligibility Screening Survey	nan	NOT_YET_RECRUITING
Renal Artery Dopplers in Twin Twin Transfusion Syndrome	nan	COMPLETED
RASopathy Biorepository	nan	RECRUITING
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)	nan	COMPLETED
Biomarkers of CASH	nan	ACTIVE_NOT_RECRUITING
Study of the Pathophysiological Mechanisms Involved in Bleeding Events	nan	COMPLETED
ADRB3, ROCK2 and GEF Levels in Overactive Bladder Patients	nan	COMPLETED
Hematological Anomalies in Children With Rasopathy	nan	RECRUITING
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP and EP300 Variants.	nan	UNKNOWN
Liquid Biopsies for the Detection of Somatic Mutations in bAVMs	nan	RECRUITING
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma	nan	COMPLETED
The Mechanism of Endogenous Nociceptin/Orphanin FQ(N/OFQ) and β1-adrenoceptor Autoantibody in Promoting Ischemic Arrhythmia in Rats	nan	NOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a RAP1A binder may also engage these)

Protein	Name	Similarity
P22123	—	1.000	P22123 →
P62833	—	1.000	P62833 →
P62836	—	1.000	P62836 →
A5A6J7	—	1.000	A5A6J7 →
Q6TEN1	—	1.000	Q6TEN1 →
P61223	—	1.000	P61223 →
P62835	—	1.000	P62835 →
Q5RDM6	—	1.000	Q5RDM6 →
Q99JI6	—	1.000	Q99JI6 →
Q9YH37	—	1.000	Q9YH37 →
Q640R7	—	1.000	Q640R7 →
P61224	—	1.000	P61224 →
Q5ZHX1	—	1.000	Q5ZHX1 →
Q4R9D4	—	1.000	Q4R9D4 →
Q62636	—	1.000	Q62636 →
A6NIZ1	—	1.000	A6NIZ1 →
Q7ZXH7	—	0.998	Q7ZXH7 →
Q94694	—	0.996	Q94694 →
P08645	—	0.995	P08645 →
Q05147	—	0.995	Q05147 →
O42277	—	0.993	O42277 →
Q9YH38	—	0.992	Q9YH38 →
Q5EFX7	—	0.992	Q5EFX7 →
Q18246	—	0.991	Q18246 →
Q95ME4	—	0.991	Q95ME4 →
P18613	—	0.990	P18613 →
Q07983	—	0.990	Q07983 →
Q61411	—	0.990	Q61411 →
Q2MJK3	—	0.990	Q2MJK3 →
P32883	—	0.990	P32883 →